3690:HKEXMeituan Class B Analysis
Data as of 2026-07-22 - not real-time
HK$83.55
Latest Price
7/10Risk
Risk Level: Medium
Executive Summary
Meituan is trading at HK$83.55, comfortably above its 20‑day (≈HK$76.7) and 50‑day (≈HK$78.1) moving averages but still below the 200‑day average (≈HK$89.6), signalling a medium‑term pullback. The RSI sits at 58, indicating modest momentum, while the MACD line sits above its signal, offering a bullish technical hint. However, volume is on a decreasing trend and 30‑day volatility is elevated at roughly 46%, suggesting price swings could be pronounced.
Fundamentally, the firm posts negative operating and net margins, negative cash flow and a debt‑to‑equity ratio near 75%, highlighting earnings and balance‑sheet pressure. Yet a forward PE of about 17.7, a price‑to‑sales near 1.4 and a consensus “buy” rating with a median target around HK$110 imply roughly 30% upside. The Fear & Greed Index sits in “Extreme Greed” territory, reflecting strong market optimism despite the underlying risk profile.
Fundamentally, the firm posts negative operating and net margins, negative cash flow and a debt‑to‑equity ratio near 75%, highlighting earnings and balance‑sheet pressure. Yet a forward PE of about 17.7, a price‑to‑sales near 1.4 and a consensus “buy” rating with a median target around HK$110 imply roughly 30% upside. The Fear & Greed Index sits in “Extreme Greed” territory, reflecting strong market optimism despite the underlying risk profile.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 5/10
Key Factors
- Decreasing volume and elevated volatility
- Price above short‑term support but below long‑term SMA200
- Negative cash flow limits immediate upside
Medium Term
1–3 yearsPositive
Model confidence: 7/10
Key Factors
- Bullish MACD crossover supporting momentum
- Analyst price targets suggest ~30% upside
- Forward PE indicates a reasonable valuation relative to peers
Long Term
> 3 yearsNeutral
Model confidence: 6/10
Key Factors
- Diversified platform and new initiatives drive growth potential
- Regulatory environment in China remains uncertain
- Leverage level requires ongoing monitoring
Key Metrics & Analysis
Financial Health
Revenue Growth5.60%
Profit Margin-10.88%
P/E Ratio17.7
ROE-24.09%
ROA-8.50%
Debt/Equity75.26
P/B Ratio2.9
Op. Cash FlowHK$-30960488448
Free Cash FlowHK$-30781749248
Technical Analysis
TrendBearish
RSI58.2
SupportHK$63.65
ResistanceHK$88.95
MA 20HK$76.73
MA 50HK$78.13
MA 200HK$89.63
MACDBullish
VolumeDecreasing
Fear & Greed Index90.98
Valuation
Target PriceHK$107.97
Upside/Downside29.23%
GradeFair
TypeBlend
Risk Assessment
Beta0.40
Volatility46.66%
Sector RiskMedium
Reg. RiskHigh
Geo RiskHigh
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.